Development of a DUSP9 Methylation Screening Assay

Pathology and Oncology Research

Volumn 21, Issue 1, 2015, Pages 123-130

  Jenner, Stefan ^a   Wiedorn, Klaus Herrmann ^a   Techel, Dieter ^a  

^a KATHARINENHOSPITAL   (Germany)

Author keywords

CIMP; Colorectal cancer; DUSP9; Promoter methylation; Pyrosequencing

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUSP9 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE;

BIOASSAY; COLON; COLORECTAL TUMOR; CPG ISLAND; GENETICS; HUMAN; METABOLISM; METHYLATION; PHENOTYPE; PROCEDURES; PROMOTER REGION;

BIOLOGICAL ASSAY; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; DUAL-SPECIFICITY PHOSPHATASES; HUMANS; METHYLATION; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; PHENOTYPE; PROMOTER REGIONS, GENETIC;

EID: 84930016936     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9797-3     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
2. Cappell MS (2005) The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin N Am 89(1):1–42
3. Wong JJ, Hawkins NJ, Ward RL (2007) Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56(1):140–148
4. Feinberg AP, Vogelstein B (1983) Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111(1):47–54
5. Rivera RM, Bennett LB (2010) Epigenetics in humans: an overview. Curr Opin Endocrinol Diabetes Obes 17(6):493–499
6. Esteller MD (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159
7. Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F et al (2011) Oncosuppressor methylation: a possible key role in colon metastatic progression. J Cell Physiol 226(7):1934–1939
8. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G et al (2006) Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 17(Suppl 7):vii97–vii102
9. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancers. Proc Natl Acad Sci U S A 96(15):8681–8686
10. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7):787–793
11. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW et al (2006) Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 30(9):1175–1183
12. Grady WM (2007) CIMP and colon cancer gets more complicated. Gut 56(11):1498–1500
13. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J et al (2009) Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4(12):e8357
14. Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27
15. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53(8):1137–1144
16. Muda M, Boschert U, Smith A, Antonsson B, Gillieron C, Chabert C et al (1997) Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J Biol Chem 272(8):5141–5151
17. Bhaduri A, Sowdhamini R (2003) A genome-wide survey of human tyrosine phosphatases. Protein Eng 16(12):881–888
18. Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6(5):391ff
19. Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418(3):475–489
20. Jeong DG, Yoon TS, Jung SK, Park BC, Park H, Ryu SE et al (2011) Exploring binding sites other than the catalytoc core in the crystal structure of catalytic domain of MKP-4. Acta Crystallogr D Biol Crystallogr 67(Pt 1):25–31
21. Nunes-Xavier C, Romá-Mateo C, Ríos P, Tárrega C, Cejudo-Marín R, Tabernero L et al (2011) Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 11(1):109–132
22. Bermudez O, Pagès G, Gimond C (2010) The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299(2):C189–C202
23. Liu Y, Lagowski J, Sundholm A, Sundberg A, Kulesz-Martin M (2007) Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4. Cancer Res 67(22):10711–10719
24. Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z et al (2011) Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer 11:413
25. Liu J, Ni W, Xiao M, Jiang F, Ni R (2013) Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma. J Gastrointest Surg 17(4):756–765
26. Keyse SM (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27(2):253–261
27. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V et al (2006) Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 103(38):14122–14127
28. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790–799
29. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101(1):124–131
30. Kondoh K, Nishida E (2007) Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773(8):1227–1237